In the last trading session, 2.53 million shares of the Connect Biopharma Holdings Ltd ADR (NASDAQ:CNTB) were traded, and its beta was -0.30. Most recently the company’s share price was $0.83, and it changed around $0.18 or 27.50% from the last close, which brings the market valuation of the company to $45.93M. CNTB currently trades at a discount to its 52-week high of $2.08, offering almost -150.6% off that amount. The share price’s 52-week low was $0.51, which indicates that the current value has risen by an impressive 38.55% since then. We note from Connect Biopharma Holdings Ltd ADR’s average daily trading volume that its 10-day average is 0.38 million shares, with the 3-month average coming to 49.23K.
Connect Biopharma Holdings Ltd ADR stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 2 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended CNTB as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight.
Connect Biopharma Holdings Ltd ADR (NASDAQ:CNTB) trade information
Instantly CNTB has showed a green trend with a performance of 27.50% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.0000 on recent trading dayincreased the stock’s daily price by 17.0%. The company’s shares are currently down -39.86% year-to-date, but still up 38.31% over the last five days. On the other hand, Connect Biopharma Holdings Ltd ADR (NASDAQ:CNTB) is 0.96% up in the 30-day period. We can see from the shorts that 5404.0 shares have been sold at a short interest cover period of 0.21 day(s).
The consensus price target as assigned by Wall Street analysts is $1.5, which translates to bulls needing to increase their stock price by 44.67% from its current value. Analyst projections state that CNTB is forecast to be at a low of $1.5 and a high of $1.5.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 7.78%. Connect Biopharma Holdings Ltd ADR earnings are expected to increase by -252.49% in 2025, but the outlook is negative -8.12% per year for the next five years.
CNTB Dividends
Connect Biopharma Holdings Ltd ADR’s next quarterly earnings report is expected to be released on 2023-Sep-11.
Connect Biopharma Holdings Ltd ADR (NASDAQ:CNTB)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 41.09% of Connect Biopharma Holdings Ltd ADR shares, and 44.76% of them are in the hands of institutional investors. The stock currently has a share float of 75.99%. Connect Biopharma Holdings Ltd ADR stock is held by 19.0 institutions, with BML CAPITAL MANAGEMENT, LLC being the largest institutional investor. By 2024-06-30, it held 3.7053% of the shares, which is about 2.04 million shares worth $3.11 million.
UBS OCONNOR LLC, with 0.9261% or 0.51 million shares worth $0.78 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
The former held 27.96 shares worth $23202.0, making up 0.05% of all outstanding shares.
